23 results
6-K
OBSVF
ObsEva SA
9 Oct 18
Current report (foreign)
4:42pm
99.1
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF
at the American Society of Reproductive Medicine
(ASRM … ) Annual Meeting
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART)
Nolasiban treatment shown
6-K
EX-99.1
OBSVF
ObsEva SA
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving … society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
.
About Kissei Pharmaceutical Co., Ltd.
Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society … through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products … ” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees
6-K
EX-99.1
sklgl9wpmx xr
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
qs6 tqe68c
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.3
p4q0dm8 i5y2
8 Nov 18
Index to Unaudited Condensed Consolidated Financial Statements
9:28am
6-K
EX-99.1
li9plf9v606z1 f4
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.3
tv7a9
7 Nov 19
Current report (foreign)
9:11am
6-K
EX-99.3
9ibnlf4eqn809q
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
49whs
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
r43qm vct
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
ayj3q7
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
20-F
m5pl 8m9aw3spi
21 Apr 17
Annual report (foreign)
12:00am
10-K
4b1eog
31 Mar 23
Annual report
4:01pm